Generics Bulletin

Coherus Partners Formycon/Bioeq File Ranibizumab With FDA

Company ‘Excited For Potential Approval In 2022’ For Lucentis Biosimilar

09 Aug 2021

Launch planning is underway for the Lucentis biosimilar that Coherus BioScienes has in-licensed in the US from Formycon and Bioeq, the US-based firm has revealed, as the eye-disease biologic was submitted to the US Food and Drug Administration.

Washington, D.C., USA- January 13, 2020: FDA Sign outside their headquarters in Washington DC. The Food and Drug Administration (FDA or USFDA) is a federal agency of the USA. — Coherus is eyeing ranibizumab and adalimumab • Source: Shutterstock

Coherus BioSciences now has two biosimilars pending before the US Food and Drug Administration, after Formycon/Bioeq submitted to the agency their biosimilar Lucentis (ranibizumab) candidate for which Coherus holds US commercialization rights.

“Our next expected biosimilar launch is CHS-201, our Lucentis biosimilar candidate,” confirmed company chairman, president and CEO Denny Lanfear, speaking...